Rapid Onsite Cytopathologic Evaluation During Endobronchial Ultrasound Bronchoscopy to Improve Molecular Marker Testing in Patients with Non-Small Cell Lung Cancer
This clinical trial evaluates the impact of rapid onsite evaluation (ROSE) during endobronchial ultrasound bronchoscopy (EBUS) on PD-L1 sufficiency in patients with non-small cell lung cancer (NSCLC). A bronchoscopy is a procedure where a doctor uses a scope with a tiny camera to go in the lungs to look for a lung nodule, or a spot. EBUS is a minimally invasive technique that uses ultrasound to produce an image of the endobronchial passages. EBUS is increasingly being used for lung cancer staging and collecting tissue for molecular markers testing. Frequently an EBUS can be diagnostic for lung cancer, there is not enough tissue for molecular testing. ROSE is an optional step during EBUS in which an onsite cytotechnologist performs a limited microscopic evaluation to provide feedback on specimens in real time during the procedure. ROSE during EBUS may decrease the rate of insufficient tumor tissue to permit next generation biomarker and PD-L1 testing in patients with NSCLC.